UPDATE: Citi Downgrades Amarin Corporation (AMRN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
MKM Lowers Fair Value, Adjusts Estimates on Amarin (AMRN) Following Q1 Results
May 12, 2014 12:19 PM EDTMKM Partners is lowering its fair value estimate on Amarin (Nasdaq: AMRN) from $2 down to $1.50, while maintaining the stock at Neutral.
Analyst Jon LeCroy commented, Vascepa prescriptions are again growing and the Kowa co-promote, scheduled to begin this month, is... More
Second-Half Vascepa Sales Growth Still in Focus for Amarin (AMRN); Aegis Maintains at 'Hold'
May 12, 2014 9:31 AM EDTAegis Capital maintains its Hold rating and $2 price target on Amarin Corp. (Nasdaq: AMRN) following Q1 results reported last week.
Analyst Ram Selvaraju Vascepa sales came in lighter than expected at $1.1 million, though R&D expenses of $11.7 million compared with the analysts... More
Amarin Corp Plc (AMRN) Posts Q1 Loss of 16c/Share; Updates on Ops
May 9, 2014 7:03 AM EDTAmarin Corp Plc (NASDAQ: AMRN) reported Q1 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.65 million.
Operational update
Commercialization and regulatory update
Amarin is now available on formulary to over 200 million lives in the United States, including over 100 million with Tier 2 coverage. As the company works to continue to increase the productivity of our sales representatives and work with our new co-promotion partner, Kowa Pharmaceuticals America, the company believes Vascepa sales will continue to... More
